CytomX Therapeutics (NASDAQ:CTMX) 報告季度每股收益$0.23，超過分析師共識預期的$(0.20)，增長215%。 與去年同期的每股收益$0.01相比增加了2200%。 公司報告季度銷售額爲$38.09百萬，超過分析師共識預期的$19.42百萬，增長96.19%。 與去年同期的銷售額$26.61百萬相比增加了43.17%。

以上內容來自Benzinga Earnings專欄，原文如下：

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $(0.20) by 215 percent. This is a 2200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $38.09 million which beat the analyst consensus estimate of $19.42 million by 96.19 percent. This is a 43.17 percent increase over sales of $26.61 million the same period last year.